<DOC>
	<DOCNO>NCT01773954</DOCNO>
	<brief_summary>To evaluate visual outcome number injection require optical coherence tomography ( OCT ) -guided treat extend regimen intravitreal aflibercept treatment subfoveal neovascular age-related macular degeneration ( NVAMD ) .</brief_summary>
	<brief_title>Repeated Eye Injections Aflibercept Treatment Wet Age Related Macular Degeneration</brief_title>
	<detailed_description>The purpose study see use `` treat extend , '' method determine often patient NVAMD visit retina clinic receive treatment , affect vision patient condition treatment . The treatment investigator use study eye injection drug call aflibercept ( also call EYLEA ) . Eylea FDA ( Food Drug Administration ) approve treatment wet age relate macular degeneration . The investigator hope `` treat extend '' strike right balance make sure patient get treatment need , give patient many treatment ( side effect treatment minimize patient n't make visit need maintain maximum visual gain ) . The experimental part study determine `` right balance '' eye injection .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients older 55 year treatment naïve , active subfoveal NVAMD demonstrate macular fluid optical coherence tomography ( OCT ) leakage fluorescein angiography ( FA ) . Only one eye patient demonstrate pretreatment acuity 20/25 20/320 eligible Patients concurrent progressive retinal disease study eye . Willing able comply clinic visit studyrelated procedure Provide sign informed consent Prior treatment NVAMD study eye , Prior experimental treatment NVAMD either eye Prior treatment systemic antiVEGF ( vascular endothelial growth factor ) agents Prior treatment verteporfin , plaque brachytherapy , externalbeam radiation therapy , transpupillary thermotherapy study eye Previous subfoveal focal laser photocoagulation involve foveal center study eye History vitreo surgical intervention study eye . Cataract surgery permit . Concurrent eye disease study eye could compromise visual acuity ( e.g . diabetic retinopathy , advanced glaucoma ) Any concurrent intraocular condition study eye ( e.g . diabetic retinopathy glaucoma ) , opinion investigator , could either require medical surgical intervention 52 week study period prevent treat visual loss might result condition , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity 52 week study period Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia , Anterior Chamber Intraocular Lens ( ACIOL ) , unstable Posterior Chamber Intraocular Lens ( PCIOL ) . Uncontrolled glaucoma study eye ( defined intraocular pressure ≥30 mmHg despite treatment antiglaucoma medication ) Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>amd</keyword>
	<keyword>age relate macular degeneration</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>neovascular</keyword>
</DOC>